Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
The non-nucleoside reverse transcriptase inhibitor VM1500A is approved for the treatment of HIV/AIDS in its N-acyl sulphonamide prodrug form elsulfavirine (Elpida®). Biochemical profiling against twelve human carbonic anhydrase (CA, EC 4.2.1.1) isoforms showed that while elsulfavirine was a weak inhibitor of all isoforms, VM1500A potently and selectively inhibited human (h) hCA VII isoform, a proven target for the therapy of neuropathic pain. The latter is a common neurologic complication of HIV infection and we hypothesise that by using Elpida® in patients may help alleviate this debilitating symptom.
Язык оригинала | английский |
---|---|
Страницы (с-по) | 1056-1060 |
Число страниц | 5 |
Журнал | Journal of Enzyme Inhibition and Medicinal Chemistry |
Том | 36 |
Номер выпуска | 1 |
DOI | |
Состояние | Опубликовано - 2021 |
ID: 77796982